Immune Design Corporation

116 articles about Immune Design Corporation

• Immune Design Corporation To Report First Quarter 2016 Financial Results

  5/3/2016

• Immune Design Corporation Announces Presentations At The 2016 ASCO Annual Meeting

  4/21/2016

• Immune Design Corporation Presents New Preclinical Data On Advances Of Two Separate Intratumoral Approaches At The AACR Annual Meeting 2016

  4/20/2016

• Immune Design Corporation Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

  3/11/2016

• Oxford BioMedica PLC Announces Expanded Collaboration And Licence With Immune Design Corporation

  3/7/2016

• Immune Design Corporation’s GLAAS Platform Shown To Modulate The Allergic Immune Response

  3/4/2016

• Immune Design Corporation To Report Fourth Quarter And Year End 2015 Financial Results

  3/3/2016

• Immune Design Corporation To Present At Cowen and Company 36th Annual Health Care Conference

  2/29/2016

• Immune Design Corporation Receives Orphan Drug Designation From The U.S. FDA For Complementary Components Of CMB305

  1/11/2016

• Immune Design Corporation Highlights G100 Preclinical Data Demonstrating Direct And Abscopal Tumor Regression, Long-Term Response And Synergy With Checkpoint Blockade

  12/8/2015

• Immune Design Corporation Highlights G100 Preclinical Data Demonstrating Direct And Abscopal Tumor Regression, Long-Term Response And Synergy With Checkpoint Blockade

  12/8/2015

• Immune Design Corporation Reports Third Quarter 2015 Financial Results

  11/13/2015

• Immune Design Corporation To Present At Jefferies Autumn 2015 Global Healthcare Conference In London

  11/11/2015

• Immune Design Corporation Announces Start Of Randomized Phase II Cancer Immunotherapy Combination Trial In Patients With Soft Tissue Sarcoma

  11/11/2015

• Immune Design Corporation To Report Third Quarter 2015 Financial Results

  11/6/2015

• Immune Design Corporation Announces Oral Presentation Of G100 Product Candidate Preclinical Data At American Society of Hematology Annual Meeting

  11/5/2015

• Immune Design Corporation Presents Preclinical Data On G100 And ZVex In Combination With Check Point Inhibitors At The 2015 Society For Immunotherapy Of Cancer Annual Meeting

  11/3/2015

• MEDI7510 For Respiratory Syncytial Virus Advances To Phase II Leverages Immune Design Corporation's GLAAS(TM) Discovery Platform

  10/29/2015

• Immune Design Corporation To Present At Leerink Partners Inaugural Immuno-Oncology Roundtable

  9/25/2015

• Immune Design Corporation To Present At Wells Fargo Securities Healthcare Conference

  9/3/2015